Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis +/- Asthma Sensitized to Dermatophagoides Pteronyssinus.

Trial Profile

Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis +/- Asthma Sensitized to Dermatophagoides Pteronyssinus.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Allergic rhinoconjunctivitis
  • Focus Pharmacodynamics
  • Sponsors Bial
  • Most Recent Events

    • 29 May 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 19 Dec 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 17 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top